Literature DB >> 26260902

Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.

Alexander Arnold1, Marcus Bahra2, Dido Lenze3, Maren Bradtmöller4, Katrin Guse4, Claire Gehlhaar4, Hendrik Bläker3, Frank L Heppner4, Arend Koch5.   

Abstract

In order to study molecular similarities and differences of intrahepatic (IH-CCA) and extrahepatic (EH-CCA) cholangiocarcinoma, 24 FFPE tumor samples (13 IH-CCA, 11 EH-CCA) were analyzed for whole genome copy number variations (CNVs) using a new high-density Molecular Inversion Probe Single Nucleotide Polymorphism (MIP SNP) assay. Common in both tumor subtypes the most frequent losses were detected on chromosome 1p, 3p, 6q and 9 while gains were mostly seen in 1q, 8q as well as complete chromosome 17 and 20. Applying the statistical GISTIC (Genomic Identification of Significant Targets in Cancer) tool we identified potential novel candidate tumor suppressor- (DBC1, FHIT, PPP2R2A) and oncogenes (LYN, FGF19, GRB7, PTPN1) within these regions of chromosomal instability. Next to common aberrations in IH-CCA and EH-CCA, we additionally found significant differences in copy number variations on chromosome 3 and 14. Moreover, due to the fact that mutations in the Isocitrate dehydrogenase (IDH-1 and IDH-2) genes are more frequent in our IH-CCA than in our EH-CCA samples, we suggest that the tumor subtypes have a different molecular profile. In conclusion, new possible target genes within regions of high significant copy number aberrations were detected using a high-density Molecular Inversion Probe Single Nucleotide Polymorphism (MIP SNP) assay, which opens a future perspective of fast routine copy number and marker gene identification for gene targeted therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Copy number aberrations; ERBB2; IDH; Molecular inversion probe

Mesh:

Substances:

Year:  2015        PMID: 26260902     DOI: 10.1016/j.yexmp.2015.08.003

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

2.  Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Authors:  Audra N Boscoe; Catherine Rolland; Robin Kate Kelley
Journal:  J Gastrointest Oncol       Date:  2019-08

Review 3.  The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma.

Authors:  Zhongguang Chen; Lili Jiang; Lifan Liang; Kelly Koral; Qian Zhang; Lei Zhao; Songjian Lu; Junyan Tao
Journal:  Am J Pathol       Date:  2021-05-14       Impact factor: 5.770

4.  Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer.

Authors:  Zhenyun Cheng; Yan Guo; Jingjing Sun; Lei Zheng
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

5.  Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

Authors:  Michele Simbolo; Caterina Vicentini; Andrea Ruzzenente; Matteo Brunelli; Simone Conci; Matteo Fassan; Andrea Mafficini; Borislav Rusev; Vincenzo Corbo; Paola Capelli; Emilio Bria; Serena Pedron; Giona Turri; Rita T Lawlor; Giampaolo Tortora; Claudio Bassi; Alfredo Guglielmi; Aldo Scarpa
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

Review 6.  Emerging role of precision medicine in biliary tract cancers.

Authors:  James M Bogenberger; Thomas T DeLeon; Mansi Arora; Daniel H Ahn; Mitesh J Borad
Journal:  NPJ Precis Oncol       Date:  2018-10-03

7.  Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.

Authors:  Helen Winter; Pamela J Kaisaki; Joe Harvey; Edoardo Giacopuzzi; Matteo P Ferla; Melissa M Pentony; Samantha J L Knight; Ricky A Sharma; Jenny C Taylor; James S O McCullagh
Journal:  Cancers (Basel)       Date:  2019-11-28       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.